Please use this identifier to cite or link to this item:
|Title:||Baseline and on-treatment predictors of chronic hepatitis B patients receiving pegylated interferon therapy in Asia|
Prince of Songkla University
|Keywords:||Immunology and Microbiology;Medicine|
|Citation:||Current Hepatitis Reports. Vol.12, No.3 (2013), 165-173|
|Abstract:||Of currently available drugs for the treatment of chronic hepatitis B, pegylated interferon (peg-IFN) offers the highest rate of off-treatment sustained response with the finite course of treatment in the absence of viral resistance. However, its clinical use is compromised by the frequent occurrence of side-effects and the uncertainty as to whether a patient will actually benefit from this treatment. It is therefore a major challenge to identify accurate predictors of sustained response to peg-IFN. These are essential for selecting the optimal candidates for peg-IFN therapy, as well as for making decisions of termination of treatment for nonresponders. This article reviews the recent knowledge focusing on the following topics: baseline and on-treatment viral and host factors in the response to peg-IFN therapy, as well as response-guided therapy for chronic hepatitis B, particularly in the Asian population. © 2013 Springer Science+Business Media New York.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.